Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series

Clinical Case Reports

卷:8

Somjit Jinapuk¹  Supat Chamnanchanunt²  Varunee Desakorn²  Vipa Thanachartwet²  Wannada Laisuan³  Suthee Leelasetakul⁴  Theerapat Racharak⁵  Duangjai Sahassananda⁶  Samlee Hapunna⁷  Sirote Khunapornphairote⁸  Manoon Surabotsophon⁹  Yingyot Klai‐On⁹ 

[1] Central Laboratory Centre Ramkhamhaeng Hospital Bangkok Thailand;

[2] Department of Clinical Tropical Medicine Faculty of Tropical Medicine Mahidol University Bangkok Thailand;

[3] Division of Allergy Immunology and Rheumatology Department of Medicine Faculty of Medicine Ramathibodi HospitalMahidol University Bangkok Thailand;

[4] Division of Oncology Department of Medicine Ramkhamhaeng Hospital Bangkok Thailand;

[5] Heart Center Department of Medicine Ramkhamhaeng Hospital Bangkok Thailand;

[6] Information Technology Unit Faculty of Tropical Medicine Mahidol University Bangkok Thailand;

[7] Intensive Care Unit Ramkhamhaeng Hospital Bangkok Thailand;

[8] Nephrology Unit Department of Medicine Ramkhamhaeng Hospital Bangkok Thailand;

[9] Pulmonary and Critical Care Division Department of Medicine Ramkhamhaeng Hospital Bangkok Thailand;

关键词: COVID‐19;    pneumonia;    acute respiratory distress syndrome;    tocilizumab;   

DOI  :  10.1002/ccr3.3407

来源: DOAJ

【 摘 要 】

Abstract Three patients diagnosed with severe COVID‐19 pneumonia received treatment with hydroxychloroquine combined with lopinavir, ritonavir, and favipiravir. Two patients diagnosed early, received tocilizumab when the pneumonia became severe and survived. The thrid patient was diagnosed late and received tocilizumab when the disease progressed to acute respiratory distress syndrome, and died.

【 授权许可】

Unknown